Sevelamer

Chemistry and pharmacology

Sevelamer consists of polyallylamine that is crosslinked with epichlorohydrin. The marketed form sevelamer hydrochloride is a partial hydrochloride salt being present as approximately 40% amine hydrochloride and 60% sevelamer base. The amine groups of sevelamer become partially protonated in the intestine and interact with phosphate ions through ionic and hydrogen bonding.

Medical uses

Sevelamer is used in the management of hyperphosphatemia in adult patients with stage 4 and 5 chronic kidney disease (CKD) on hemodialysis. Its efficacy at lowering phosphate levels is similar to that of calcium acetate, but without the accompanying risk of hypercalcemia and arterial calcification. In patients with CKD, it has also been shown to reduce LDL and cholesterol.

Contraindications

Sevelamer therapy is contraindicated in hypophosphatemia or bowel obstruction. In hypophosphatemia, sevelamer could exacerbate the condition by further lowering phosphate levels in the blood, which could be fatal.

Adverse effects

Common adverse drug reactions (ADRs) associated with the use of sevelamer include: nausea and vomiting, constipation, diarrhea, stomach pain, heartburn, gas.

Other effects

Sevelamer can significantly reduce serum uric acid. This reduction has no known detrimental effect and may be helpful in patients with gout.

Sevelamer is able to sequester advanced glycation end products (AGEs) in the gut, preventing their absorption into the blood. AGEs contribute to oxidative stress, which can damage cells (like beta cells, which produce insulin in the pancreas). As Vlassara and Uribarri explain in a 2014 review on AGEs, this may explain why sevelamer, but not calcium carbonate (a phosphate binder that does not sequester AGEs), has been shown to lower AGEs in the blood, as well as oxidative stress and inflammatory markers.

References

References

1. (21 June 2022). "Prescription medicines: registration of new chemical entities in Australia, 2015".
2. (9 May 2018). "Kidney disease".
3. (10 June 2009). "Renvela EPAR".
4. (12 June 2009). "Renvela PI".
5. (15 January 2015). "Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva) EPAR".
6. (19 January 2015). "Sevelamer carbonate PI".
7. (28 January 2000). "Renagel EPAR".
8. (June 1999). "Renagel: a new and different phosphate binder". ANNA Journal.
9. (September 2000). "Renagel: reducing serum phosphorus in haemodialysis patients". Hospital Medicine.
10. (January 2017). "The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis". Nephrology, Dialysis, Transplantation.
11. (February 2016). "Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials". Clinical Journal of the American Society of Nephrology.
12. Yuste, Claudia. (2017). "Gastrointestinal complications induced by sevelamer crystals". Clinical Kidney Journal.
13. (September 2004). "A comparison of clinically useful phosphorus binders for patients with chronic kidney failure". Kidney International Supplements.
14. "Sevelamer".
15. (May 2015). "Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders". Expert Review of Cardiovascular Therapy.
16. (January 2014). "Advanced glycation end products (AGE) and diabetes: cause, effect, or both?". Current Diabetes Reports.